Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVEO NASDAQ:GLTO NASDAQ:TYME NASDAQ:XERS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVEOAVEO Pharmaceuticals$15.00$14.97$3.06▼$15.00$521.45M1601,442 shs247,800 shsGLTOGalecto$9.58-12.8%$4.98$2.01▼$31.70$14.56M1.387.63 million shs89,585 shsTYMETyme Technologies$0.31$0.30$0.22▼$1.14$53.51M0.931.01 million shs2.68 million shsXERSXeris Biopharma$9.24+1.1%$7.90$2.82▼$9.41$1.48B0.392.41 million shs2.57 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVEOAVEO Pharmaceuticals0.00%0.00%0.00%0.00%0.00%GLTOGalecto-12.83%-24.33%+236.14%+166.85%+42.77%TYMETyme Technologies0.00%0.00%0.00%0.00%0.00%XERSXeris Biopharma+1.09%+15.64%+20.47%+80.82%+203.95%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVEOAVEO Pharmaceuticals$15.00$14.97$3.06▼$15.00$521.45M1601,442 shs247,800 shsGLTOGalecto$9.58-12.8%$4.98$2.01▼$31.70$14.56M1.387.63 million shs89,585 shsTYMETyme Technologies$0.31$0.30$0.22▼$1.14$53.51M0.931.01 million shs2.68 million shsXERSXeris Biopharma$9.24+1.1%$7.90$2.82▼$9.41$1.48B0.392.41 million shs2.57 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVEOAVEO Pharmaceuticals0.00%0.00%0.00%0.00%0.00%GLTOGalecto-12.83%-24.33%+236.14%+166.85%+42.77%TYMETyme Technologies0.00%0.00%0.00%0.00%0.00%XERSXeris Biopharma+1.09%+15.64%+20.47%+80.82%+203.95%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVEOAVEO Pharmaceuticals 0.00N/AN/AN/AGLTOGalecto 1.00SellN/AN/ATYMETyme Technologies 0.00N/AN/AN/AXERSXeris Biopharma 2.75Moderate Buy$7.08-23.34% DownsideCurrent Analyst Ratings BreakdownLatest TYME, AVEO, GLTO, and XERS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025GLTOGalectoWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/13/2025XERSXeris BiopharmaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/8/2025XERSXeris BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025GLTOGalectoWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025XERSXeris BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)8/19/2025XERSXeris BiopharmaLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$7.00 ➝ $9.008/12/2025XERSXeris BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.00(Data available from 10/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVEOAVEO Pharmaceuticals$42.29M12.33N/AN/A$1.33 per share11.28GLTOGalectoN/AN/AN/AN/A$10.99 per shareN/ATYMETyme TechnologiesN/AN/AN/AN/A$0.47 per shareN/AXERSXeris Biopharma$203.07M7.35N/AN/A($0.20) per share-46.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVEOAVEO Pharmaceuticals-$53.34M-$0.84N/A28.85N/A-30.79%-81.66%-28.83%N/AGLTOGalecto-$21.44M-$13.13N/AN/AN/AN/A-115.70%-95.42%11/7/2025 (Estimated)TYMETyme Technologies-$23.63M-$0.14N/A∞N/AN/A-28.30%-26.21%N/AXERSXeris Biopharma-$54.84M-$0.21N/AN/AN/A-13.01%N/A-8.00%11/14/2025 (Estimated)Latest TYME, AVEO, GLTO, and XERS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/14/2025Q3 2025XERSXeris Biopharma$0.01N/AN/AN/AN/AN/A8/7/2025Q2 2025XERSXeris Biopharma-$0.03-$0.01+$0.02-$0.01$64.58 million$67.71 million8/5/2025Q2 2025GLTOGalectoN/A-$2.60N/A-$2.60N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVEOAVEO PharmaceuticalsN/AN/AN/AN/AN/AGLTOGalectoN/AN/AN/AN/AN/ATYMETyme TechnologiesN/AN/AN/AN/AN/AXERSXeris BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVEOAVEO Pharmaceuticals0.942.372.35GLTOGalectoN/A4.964.96TYMETyme TechnologiesN/A14.0614.06XERSXeris BiopharmaN/A1.951.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVEOAVEO Pharmaceuticals49.95%GLTOGalecto14.20%TYMETyme Technologies16.69%XERSXeris Biopharma42.75%Insider OwnershipCompanyInsider OwnershipAVEOAVEO Pharmaceuticals3.29%GLTOGalecto10.80%TYMETyme Technologies16.90%XERSXeris Biopharma6.47%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVEOAVEO Pharmaceuticals11434.76 million33.62 millionOptionableGLTOGalecto401.32 million1.18 millionOptionableTYMETyme Technologies17172.21 million143.10 millionOptionableXERSXeris Biopharma290161.48 million151.03 millionOptionableTYME, AVEO, GLTO, and XERS HeadlinesRecent News About These CompaniesXeris Biopharma (NASDAQ:XERS) Raised to Strong-Buy at Wall Street ZenOctober 18 at 2:56 AM | marketbeat.comXeris Biopharma (XERS) Surges 14.2%: Is This an Indication of Further Gains?October 16 at 10:11 AM | zacks.comXeris Biopharma (NASDAQ:XERS) Sets New 52-Week High - Time to Buy?October 15 at 2:16 PM | marketbeat.comXeris Biopharma (NASDAQ:XERS) Upgraded to Strong-Buy at Zacks ResearchOctober 15 at 7:45 AM | marketbeat.comBeat the Market the Zacks Way: MariMed, Xeris Biopharma, Lam Research in FocusOctober 13, 2025 | finance.yahoo.comBrokerages Set Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Price Target at $7.08October 9, 2025 | americanbankingnews.comWeiss Ratings Reiterates Sell (D-) Rating for Xeris Biopharma (NASDAQ:XERS)October 8, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Stock Price Down 4% - Here's What HappenedOctober 8, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of "Moderate Buy" from AnalystsOctober 6, 2025 | marketbeat.comXeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 3, 2025 | businesswire.comXeris Biopharma (XERS) is a Great Momentum Stock: Should You Buy?October 3, 2025 | zacks.comXeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?October 3, 2025 | zacks.comXeris Biopharma (NASDAQ:XERS) Hits New 12-Month High - Time to Buy?October 2, 2025 | marketbeat.comStrs Ohio Buys New Holdings in Xeris Biopharma Holdings, Inc. $XERSSeptember 24, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Stock Price Down 7.2% - Should You Sell?September 20, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Sets New 52-Week High - Should You Buy?September 19, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Director Sells $119,660.00 in StockSeptember 13, 2025 | insidertrades.comWhat Makes Xeris Biopharma (XERS) a Strong Momentum Stock: Buy Now?September 9, 2025 | zacks.comXeris In Recorlev-Fuelled Growth: Why I Choose To BuySeptember 5, 2025 | seekingalpha.comJeffrey Sherman Sells 42,232 Shares of Xeris Biopharma (NASDAQ:XERS) StockAugust 30, 2025 | insidertrades.comXeris Biopharma Holdings, Inc. (XERS) Reports Record $71.5M Q2 RevenueAugust 29, 2025 | uk.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTYME, AVEO, GLTO, and XERS Company DescriptionsAVEO Pharmaceuticals NASDAQ:AVEOAVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.Galecto NASDAQ:GLTO$9.58 -1.41 (-12.83%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$9.62 +0.04 (+0.38%) As of 10/17/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.Tyme Technologies NASDAQ:TYMETyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.Xeris Biopharma NASDAQ:XERS$9.24 +0.10 (+1.09%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$9.35 +0.11 (+1.14%) As of 10/17/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Intel's Turnaround Hits Hyperspeed With A New 52-Week High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
